TherapeuticsMD (NASDAQ: TXMD)
TherapeuticsMD Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
TherapeuticsMD Company Info
TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.
News & Analysis
3 Awful Stocks Robinhood Investors Love -- and 1 of the Best
Pharmaceutical stocks are popular with Robinhood Investors, including three I would stay away from and one that I wouldn't.
3 Biotech Stocks Robinhood Investors Love, and 1 They Should
Two biotechs have big risks, one is a buy, and the other is a big opportunity to consider.
3 Drug Stocks That Could Soar in 2020
Have extra cash to spare? These drug stocks are significantly undervalued and could make you wealthy in the long run.
Here's Why TherapeuticsMD Stock Is Rocketing Higher Today
A newly issued patent could provide market exclusivity for its long-term contraceptive device.
Is TherapeuticsMD Stock a Buy?
The company already has three women's healthcare products available on the market.
Why TherapeuticsMD's Stock Jumped Today
Shares pop after an SEC filing reveals that the biopharma has attracted the attention of a major financial institution.
Here's Why TherapeuticsMD Fell as Much as 21.5% Today
Investors are bracing for dilution from a proposed share offering.
Here's Why TherapeuticsMD Jumped 25.6% in September
The path ahead is looking a bit brighter for this women's-health-focused pharmaceutical company.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.